Chengdu Origen and Vanotech have initiated the first subject dosing in the Phase I trial, VAN-2401, of KH658 for treating wet ...

OBI Pharma has received clearance from the US FDA for an IND application for OBI-902 to begin a Phase I/II trial for advanced ...

AstraZeneca plans to submit the positive data Breztri Aerosphere in asthma for to regulatory authorities for review.

Amylyx has dosed the first subject in the Phase III LUCIDITY trial of avexitide for treating post-bariatric hypoglycaemia ...

Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research ...

Tempus AI has announced that it is using the TIME Network for Phase I trials to expedite site activation and enrolment.

BioCardia has announced the enrolment of the first subject in CardiAMP HF II trial of its cell therapy for treating heart ...

Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the ...

Neurocrine has commenced a Phase III registrational programme to assess NBI-1117568 as a treatment for schizophrenia in adult ...

The US FDA has confirmed proteinuria as an acceptable primary endpoint in Dimerix ‘s Phase III ACTION3 trial of DMX-200 for ...

The upcoming 12th Annual Clinical Trials in Oncology conference will cover a wide range of topics on clinical research in ...

The FDA approved AstraZeneca's Truqap in November 2023 for the treatment of advanced HR-positive breast cancer.